2844 related articles for article (PubMed ID: 18272264)
1. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
2. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.
Vandepapelière P; Rehermann B; Koutsoukos M; Moris P; Garçon N; Wettendorff M; Leroux-Roels G
Vaccine; 2005 Apr; 23(20):2591-601. PubMed ID: 15780441
[TBL] [Abstract][Full Text] [Related]
3. Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses.
Schiött A; Larsson K; Manniche S; Kalliomäki S; Heydenreich AV; Dalsgaard K; Kirkby N
Int J Pharm; 2011 Jul; 414(1-2):312-20. PubMed ID: 21601626
[TBL] [Abstract][Full Text] [Related]
4. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
Leroux-Roels G; Van Belle P; Vandepapeliere P; Horsmans Y; Janssens M; Carletti I; Garçon N; Wettendorff M; Van Mechelen M
Vaccine; 2015 Feb; 33(8):1084-91. PubMed ID: 25444781
[TBL] [Abstract][Full Text] [Related]
5. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
[TBL] [Abstract][Full Text] [Related]
6. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
[TBL] [Abstract][Full Text] [Related]
7. [Cellular immune responses of recombinant hepatitis B (rHB) vaccine and HBsAG derived from Hansenula polymorpha cells].
Hu ZY; He P; Zhang R; Fang X; Zhu FC; Qiu SH; Li HM; Wang H; Liang ZL; Zhuang H
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jul; 29(7):706-11. PubMed ID: 19031766
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma.
Böcher WO; Herzog-Hauff S; Schlaak J; Meyer zum Büschenfeld KH; Löhr HF
Hepatology; 1999 Jan; 29(1):238-44. PubMed ID: 9862872
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
[TBL] [Abstract][Full Text] [Related]
10. CpG oligonucleotides induce strong humoral but only weak CD4+ T cell responses to protein antigens in rhesus macaques in vivo.
Hartmann G; Marschner A; Viveros PR; Stahl-Hennig C; Eisenblätter M; Suh YS; Endres S; Tenner-Racz K; Uberla K; Racz P; Steinman RM; Ignatius R
Vaccine; 2005 May; 23(25):3310-7. PubMed ID: 15837237
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses.
Qiao M; Murata K; Davis AR; Jeong SH; Liang TJ
Hepatology; 2003 Jan; 37(1):52-9. PubMed ID: 12500188
[TBL] [Abstract][Full Text] [Related]
12. The adjuvant effects of co-stimulatory molecules on cellular and memory responses to HBsAg DNA vaccination.
Du X; Zheng G; Jin H; Kang Y; Wang J; Xiao C; Zhang S; Zhao L; Chen A; Wang B
J Gene Med; 2007 Feb; 9(2):136-46. PubMed ID: 17310492
[TBL] [Abstract][Full Text] [Related]
13. Cytokine-containing liposomes as vaccine adjuvants.
Lachman LB; Ozpolat B; Rao XM
Eur Cytokine Netw; 1996 Dec; 7(4):693-8. PubMed ID: 9010671
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
Cooper CL; Davis HL; Morris ML; Efler SM; Krieg AM; Li Y; Laframboise C; Al Adhami MJ; Khaliq Y; Seguin I; Cameron DW
Vaccine; 2004 Aug; 22(23-24):3136-43. PubMed ID: 15297066
[TBL] [Abstract][Full Text] [Related]
15. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.
Ma R; Du JL; Huang J; Wu CY
Biochem Biophys Res Commun; 2007 Sep; 361(2):537-42. PubMed ID: 17662694
[TBL] [Abstract][Full Text] [Related]
16. Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant.
Chaitra MG; Nayak R; Shaila MS
Vaccine; 2007 Oct; 25(41):7168-76. PubMed ID: 17709160
[TBL] [Abstract][Full Text] [Related]
17. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen.
Rahman F; Dahmen A; Herzog-Hauff S; Böcher WO; Galle PR; Löhr HF
Hepatology; 2000 Feb; 31(2):521-7. PubMed ID: 10655280
[TBL] [Abstract][Full Text] [Related]
18. Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells.
Bauer T; Günther M; Bienzle U; Neuhaus R; Jilg W
Liver Transpl; 2007 Mar; 13(3):434-42. PubMed ID: 17318860
[TBL] [Abstract][Full Text] [Related]
19. PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA.
Shen E; Li L; Li L; Feng L; Lu L; Yao Z; Lin H; Wu C
Cell Mol Immunol; 2007 Apr; 4(2):113-20. PubMed ID: 17484805
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials.
Leroux-Roels I; Devaster JM; Leroux-Roels G; Verlant V; Henckaerts I; Moris P; Hermand P; Van Belle P; Poolman JT; Vandepapelière P; Horsmans Y
Vaccine; 2015 Jan; 33(4):577-84. PubMed ID: 24176494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
